StocksMedium•16 November 2026•
1 min read
Vivos Therapeutics Revenue Up 24% in Q3 as Company Regains Nasdaq Compliance
Key Facts
1Vivos Therapeutics revenue increased 24% quarter-over-quarter.
2Third quarter operating loss improved 18% year-over-year due to cost reductions.
3The company regained compliance with the Nasdaq stockholders' equity requirement.
Vivos Therapeutics revenue increased 24% quarter-over-quarter according to a GlobeNewswire report on the company's Q3 2026 financial results. The company stated that third-quarter operating loss improved 18% year-over-year due to strategic cost reductions, and it has officially regained compliance with the Nasdaq stockholders' equity requirement.
VVOS closed at $0.098 on November 13, 2026, with a daily high of $0.0985 and a daily low of $0.09145. These financial improvements occur as Vivos Therapeutics strengthens its balance sheet following the restoration of its exchange listing requirements.